Create a narrative

Longeveron Community

NasdaqCM:LGVN Community

1 Narratives written by author
1 Comments on narratives written by author
7 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

ELPIS II And Alzheimer Programs Will Accelerate FDA Approval

Key Takeaways Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships. Cost-management strategies in 2024 are set to improve margins and support key clinical trials, enhancing long-term earnings prospects.

US$8.88

FV

82.4% undervalued

124.15%

Revenue growth p.a.

0

0

7

3 days ago